Skip to Content

Cyclacel Pharmaceuticals Inc CYCC

Morningstar Rating
$2.90 +0.34 (13.28%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CYCC is trading at a 66% discount.
Price
$2.92
Fair Value
$6.39
Uncertainty
Extreme
1-Star Price
$49.85
5-Star Price
$4.65
Economic Moat
Lhwt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYCC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.56
Day Range
$2.502.90
52-Week Range
$2.0013.20
Bid/Ask
$2.90 / $2.99
Market Cap
$3.82 Mil
Volume/Avg
1,089 / 187,928

Key Statistics

Price/Earnings (Normalized)
Price/Sales
6.25
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
12

Valuation

Metric
CYCC
Price/Earnings (Normalized)
Price/Book Value
0.57
Price/Sales
6.25
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
CYCC
Quick Ratio
1.12
Current Ratio
1.36
Interest Coverage
Quick Ratio
CYCC

Profitability

Metric
CYCC
Return on Assets (Normalized)
−106.23%
Return on Equity (Normalized)
−154.75%
Return on Invested Capital (Normalized)
−155.97%
Return on Assets
CYCC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGvz$550.4 Bil
VRTX
Vertex Pharmaceuticals IncGhdgbd$111.8 Bil
REGN
Regeneron Pharmaceuticals IncZhsbmq$107.9 Bil
MRNA
Moderna IncBmhpn$36.3 Bil
ARGX
argenx SE ADRHrls$23.0 Bil
BNTX
BioNTech SE ADRHph$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncGqmrjt$19.2 Bil
BMRN
Biomarin Pharmaceutical IncBymgcd$16.4 Bil
RPRX
Royalty Pharma PLC Class AFnwyy$13.4 Bil
INCY
Incyte CorpYqzbpvd$13.3 Bil

Sponsor Center